This review assessed the efficacy of calcium antagonists for reducing mortality and complications following coronary artery bypass graft or valve surgery. The authors concluded that treatment reduced complications but not mortality. The review had some methodological and reporting limitations (participant characteristics were not reported), but the authors' conclusions were conservative and appear likely to be reliable
Data extraction
Two reviewers independently abstracted the data onto standardized forms. The details abstracted were the patient characteristics, the type of surgery, treatments and outcomes. Treatment effects, odds ratios (OR) with 95% confidence intervals (CI), or weighted mean differences were calculated for the individual studies.
Methods of synthesis
How were the studies combined? The studies were combined using a random-effects model to estimate the pooled treatment effects: OR with 95% CI for dichotomous outcomes and weighted mean differences for continuous outcomes. Funnel plots were used to investigate publication bias. A fixed-effect model was used to compare adverse events and prior medication use.
Primary analyses were the effects of CAs on the outcomes listed above. Secondary analyses were performed for each class of CA (diltiazem, verapamil, dihydropyridines) and for CAs compared specifically against nitroglycerin.
How were differences between studies investigated?
The Q test was used to investigate heterogeneity between the studies. The authors also conducted sensitivity analyses to investigate the effect of excluding the studies with the most favourable CA treatment effects, and the effect of study quality.
Results of the review
Forty-one studies (3,327 patients) were included: 36 (2,914 patients) following coronary artery bypass graft surgery, 2 (221 patients) following valve surgery and 3 (192 patients) following mixed types of surgery.
The authors stated that the majority of the included studies were unblinded. The median Jadad score was 1 (range: 1 to 4). Funnel plots were not presented, but the authors stated that they did not indicate the presence of publication bias.
CAs did not affect mortality (n=11); the OR was 1.01 (95% CI: 0.46, 2.22, P=1). When nimodipine studies were excluded, the OR was 0.66 (95% CI: 0.26, 1.70, P=0.4). There was no significant heterogeneity.
CAs significantly reduced MI (n=22); the OR was 0.58 (95% CI: 0.37, 0.91, P=0.02). There was no significant heterogeneity.
CAs significantly reduced ischaemia (n=20); the OR was 0.53 (95% CI: 0.39, 0.72, P<0.001). There was no significant heterogeneity.
CAs did not significantly reduce SVT (n=15); the OR was 0.73 (95% CI: 0.48, 1.12, P=0.15). There was significant heterogeneity among the studies. Subgroup analyses indicated that non-dihydropyridines significantly reduced SVT (OR 0.62, 95% CI: 0.41, 0.93, P=0.02), whereas dihydropyridines non significantly increased SVT (OR 2.69, 95% CI: 0.57, 12.64, P=0.2).
CAs increased post-operative creatinine clearance non significantly (n=5); the increase was 7.65 mL/minute (95% CI: -4.21, 19.51, P=0.2). There was significant heterogeneity between the studies. Post-hoc analyses were conducted to investigate this heterogeneity.
There were no significant differences between the CA and non-CA arms of the studies in any of the adverse events investigated.
Further results, including the effects of individual drugs, post-hoc, secondary and subgroup analyses, were reported in the review.
